✦ LIBER ✦

Oral etoposide in the treatment of hormone-refractory prostate cancer

✍ Scribed by Maha H. Hussain; Kenneth J. Pienta; Bruce G. Redman; Glenn D. Cummings; Lawrence E. Flaherty

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 340 KB
Volume: 74
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19940701)74:1<100::aid-cncr2820740118>3.0.co;2-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of the oral cyclophospham

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. Chrétien; Sy 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 1 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum

The use of flutamide in hormone-refracto

The use of flutamide in hormone-refractory metastatic prostate cancer

✍ D. G. McLeod; R. C. Benson Jr; M. A. Eisenberger; E. D. Crawford; B. A. Blumenst 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

Circulating levels of interleukin-6 in p

Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer

✍ Drachenberg, Darrel E.; Elgamal, Abdel-Aziz A.; Rowbotham, Ron; Peterson, Mary; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 2 views

BACKGROUND. ) is a cytokine that plays a central role in host defense due to its wide range of immune and hematopoietic activities. It is found in high levels in human ejaculate, and has recently been found to regulate prostate-specific protein expression in prostate cancer cells through nonsteroida

Chemotherapy for hormone-refractory pros

Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder

✍ Tomasz Beer; Derek Raghavan 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

A phase II trial of estramustine and eto

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)

✍ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40±50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-®ve patients were accrued over

Radical prostatectomy in the treatment o

Radical prostatectomy in the treatment of prostatic cancer

✍ Ormond S. Culp; James J. Meyer 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 1 views

The legitimate role of radical prostatectomy remains controversial. A prospective study was started at the Mayo Clinic in 1950 to evaluate therapeutic usefulness of the operation. Rigid criteria were established for selection of surgical candidates. From 1950 through 1972, 264 patients had radical p